BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 29378530)

  • 21. [Effects of intravitreal pegaptanib or bevacizumab and laser in treatment of threshold retinopathy of prematurity in zone I and posterior zone II--four years results].
    Autrata R; Senková K; Holousová M; Krejcírová I; Dolezel Z; Borek I
    Cesk Slov Oftalmol; 2012 Feb; 68(1):29-36. PubMed ID: 22679695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of anti-vascular endothelial growth factor in treatment of retinopathy of prematurity-a current review.
    Chow SC; Lam PY; Lam WC; Fung NSK
    Eye (Lond); 2022 Aug; 36(8):1532-1545. PubMed ID: 35017699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complications of retinopathy of prematurity treatment.
    Barnett JM; Hubbard GB
    Curr Opin Ophthalmol; 2021 Sep; 32(5):475-481. PubMed ID: 34231532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
    Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A proposal of an algorithm for the diagnosis and treatment of recurrence or treatment failure of retinopathy of prematurity after anti-VEGF therapy based on a large case series.
    Martínez-Castellanos MA; González-H León A; Romo-Aguas JC; Gonzalez-Gonzalez LA
    Graefes Arch Clin Exp Ophthalmol; 2020 Apr; 258(4):767-772. PubMed ID: 31953595
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis.
    Wang SD; Zhang GM;
    Int J Ophthalmol; 2020; 13(5):806-815. PubMed ID: 32420230
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of refractive error in children treated for retinopathy of prematurity with anti-vascular endothelial growth factor (anti-VEGF) agents: A meta-analysis and systematic review.
    Tan QQ; Christiansen SP; Wang J
    PLoS One; 2019; 14(12):e0225643. PubMed ID: 31790445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of vascular endothelial growth factor and related factors after intravitreous bevacizumab injection for retinopathy of prematurity.
    Wu WC; Lien R; Liao PJ; Wang NK; Chen YP; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC
    JAMA Ophthalmol; 2015 Apr; 133(4):391-7. PubMed ID: 25569026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-Vascular Endothelial Growth Factor Preparations in the Treatment of Retinopathy of Prematurity: Balancing Risks and Benefits.
    Chawla D; Darlow BA
    Indian Pediatr; 2016 Nov; 53 Suppl 2():S129-S136. PubMed ID: 27915321
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of Retinopathy of Prematurity--Use of Anti-VEGF Therapy.
    Tran KD; Cernichiaro-Espinosa LA; Berrocal AM
    Asia Pac J Ophthalmol (Phila); 2018; 7(1):56-62. PubMed ID: 29376233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on the Use of Anti-VEGF Drugs in the Treatment of Retinopathy of Prematurity.
    Seery CW; Betesh S; Guo S; Zarbin MA; Bhagat N; Wagner RS
    J Pediatr Ophthalmol Strabismus; 2020 Nov; 57(6):351-362. PubMed ID: 33211892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment for retinopathy of prematurity in Sweden 2008-2021: Reduced gestational age of treated infants and remaining differences in treatment type and recurrence rates between hospitals.
    Holmström G; Hellström A; Teär Fahnehjelm K; Gränse L; Sandgren Hochhard K; Sunnqvist B; Tornqvist K; Tsamadou D; Wallin A; Larsson E
    Acta Ophthalmol; 2024 Jun; 102(4):401-408. PubMed ID: 37698061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increase in treatment of retinopathy of prematurity in the Netherlands from 2010 to 2017.
    Trzcionkowska K; Vehmeijer WBHJ; Kerkhoff FT; Bauer NJC; Bennebroek CAM; Dijk PH; Dijkman KP; van den Dungen FAM; Eggink CA; Feenstra RPG; Groenendaal F; van Heijst AF; van der Hoeven MAHBM; Kornelisse RF; Kraal-Biezen E; Lopriore E; Onland W; Renardel de Lavalette VW; van Rijn LJ; Schuerman FABA; Simonsz HJ; Voskuil-Kerkhof ESM; Witlox RSGM; Termote JUM; Schalij-Delfos NE
    Acta Ophthalmol; 2021 Feb; 99(1):97-103. PubMed ID: 32701185
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
    Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
    Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Five years of treatment for retinopathy of prematurity in Sweden: results from SWEDROP, a national quality register.
    Holmström G; Hellström A; Jakobsson P; Lundgren P; Tornqvist K; Wallin A
    Br J Ophthalmol; 2016 Dec; 100(12):1656-1661. PubMed ID: 26969711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcomes after Intravitreal Bevacizumab versus Laser Photocoagulation for Retinopathy of Prematurity: A 5-Year Retrospective Analysis.
    Hwang CK; Hubbard GB; Hutchinson AK; Lambert SR
    Ophthalmology; 2015 May; 122(5):1008-15. PubMed ID: 25687024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current Practice Patterns for Treatment of Retinopathy of Prematurity.
    Tawse KL; Jeng-Miller KW; Baumal CR
    Ophthalmic Surg Lasers Imaging Retina; 2016 May; 47(5):491-5. PubMed ID: 27183557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravitreal bevacizumab for retinopathy of prematurity: refractive error results.
    Harder BC; Schlichtenbrede FC; von Baltz S; Jendritza W; Jendritza B; Jonas JB
    Am J Ophthalmol; 2013 Jun; 155(6):1119-1124.e1. PubMed ID: 23490192
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of vascular leakage and its development with FFA among patients treated with intravitreal anti-VEGF due to aggressive posterior ROP.
    Ekinci DY; Vural AD; Bayramoglu SE; Onur IU; Hergunsel GO
    Int Ophthalmol; 2019 Dec; 39(12):2697-2705. PubMed ID: 30830544
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Long-term effects of anti-VEGF therapy for retinopathy of prematurity].
    Krohne TU; Müller A; Larsen PP; Holz FG
    Ophthalmologe; 2018 Jun; 115(6):464-468. PubMed ID: 29654389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.